[{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"35c5e79b-54b0-43e1-b61a-1b50d58d242e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06725173","created_at":"2025-02-25T14:43:58.802Z","updated_at":"2025-02-25T14:43:58.802Z","phase":"","brief_title":"Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.","source_id_and_acronym":"NCT06725173","lead_sponsor":"University of Washington","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-14"},{"id":"a532ecf0-a3c8-400f-b42b-9187fc8e7481","acronym":"RIVERBOAT","url":"https://clinicaltrials.gov/study/NCT03932786","created_at":"2021-01-18T19:22:16.373Z","updated_at":"2024-07-02T16:35:04.323Z","phase":"","brief_title":"Studying Health Outcomes After Treatment in Patients With Retinoblastoma","source_id_and_acronym":"NCT03932786 - RIVERBOAT","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-05-10"},{"id":"447deee0-48df-4d5d-a0f4-8e3810a39c90","acronym":"DepiSCARRH","url":"https://clinicaltrials.gov/study/NCT03026998","created_at":"2021-01-18T14:53:55.583Z","updated_at":"2024-07-02T16:35:06.766Z","phase":"","brief_title":"MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)","source_id_and_acronym":"NCT03026998 - DepiSCARRH","lead_sponsor":"Institut Curie","biomarkers":" RB1","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/19/2017","start_date":" 03/19/2017","primary_txt":" Primary completion: 03/01/2034","primary_completion_date":" 03/01/2034","study_txt":" Completion: 03/01/2034","study_completion_date":" 03/01/2034","last_update_posted":"2024-04-30"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"2a4bf351-5891-4378-a18a-58000cb4e271","acronym":"","url":"https://clinicaltrials.gov/study/NCT00342797","created_at":"2021-01-18T01:11:06.648Z","updated_at":"2024-07-02T16:35:15.944Z","phase":"","brief_title":"Retinoblastoma Biomarker Study","source_id_and_acronym":"NCT00342797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 2136","initiation":"Initiation: 11/17/1993","start_date":" 11/17/1993","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 03/06/2024","study_completion_date":" 03/06/2024","last_update_posted":"2024-03-07"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2025-02-25T14:00:01.019Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"},{"id":"3aa93ea7-c48b-4971-8c33-db396bab8cda","acronym":"rbliqbx","url":"https://clinicaltrials.gov/study/NCT04959097","created_at":"2021-07-13T12:53:20.354Z","updated_at":"2024-07-02T16:35:20.313Z","phase":"","brief_title":"RB Liquid Biopsy Biorepository","source_id_and_acronym":"NCT04959097 - rbliqbx","lead_sponsor":"Children's Hospital Los Angeles","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-02-07"},{"id":"151a9d64-fe72-45af-9af7-b34da084781c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01661400","created_at":"2021-01-18T07:10:35.641Z","updated_at":"2024-07-02T16:35:21.403Z","phase":"Phase 1","brief_title":"Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors","source_id_and_acronym":"NCT01661400","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • thalidomide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/26/2012","start_date":" 10/26/2012","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2023","study_completion_date":" 12/27/2023","last_update_posted":"2024-01-31"},{"id":"3c9529ef-684d-40e0-abc9-1500bd742be6","acronym":"BrUOG 387","url":"https://clinicaltrials.gov/study/NCT05655598","created_at":"2022-12-19T14:58:37.717Z","updated_at":"2024-07-02T16:35:36.916Z","phase":"Phase 1","brief_title":"TAS-116 Plus Palbociclib in Breast and Rb-[] Cancer","source_id_and_acronym":"NCT05655598 - BrUOG 387","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Jeselhy (pimitespib)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-09-14"},{"id":"71483d11-4da8-4e39-ba54-3c80e749d899","acronym":"NIRBTEST","url":"https://clinicaltrials.gov/study/NCT04164134","created_at":"2021-01-18T20:19:15.421Z","updated_at":"2024-07-02T16:35:42.030Z","phase":"","brief_title":"New Strategies to Detect Cancers in Carriers of Mutations in RB1","source_id_and_acronym":"NCT04164134 - NIRBTEST","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 378","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-07-25"},{"id":"fb76e3be-1fa8-41fb-ba96-a942800db45c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02193724","created_at":"2021-01-18T10:14:45.089Z","updated_at":"2024-07-02T16:36:39.707Z","phase":"","brief_title":"Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma","source_id_and_acronym":"NCT02193724","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" RB1 • MYCN","pipe":" | ","alterations":" MYCN amplification • RB1 mutation","tags":["RB1 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/04/2014","start_date":" 11/04/2014","primary_txt":" Primary completion: 08/23/2019","primary_completion_date":" 08/23/2019","study_txt":" Completion: 08/23/2019","study_completion_date":" 08/23/2019","last_update_posted":"2020-10-23"},{"id":"b649f008-89ac-4680-b5d8-7116ee311615","acronym":"","url":"https://clinicaltrials.gov/study/NCT01331135","created_at":"2021-01-18T05:25:33.023Z","updated_at":"2024-07-02T16:36:44.643Z","phase":"Phase 1","brief_title":"Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors","source_id_and_acronym":"NCT01331135","lead_sponsor":"Emory University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 08/09/2017","primary_completion_date":" 08/09/2017","study_txt":" Completion: 08/09/2017","study_completion_date":" 08/09/2017","last_update_posted":"2020-05-29"},{"id":"65879970-940d-49a4-bf2d-eb502d2401a1","acronym":"AflacST1402","url":"https://clinicaltrials.gov/study/NCT02390843","created_at":"2021-01-18T11:23:57.025Z","updated_at":"2024-07-02T16:36:46.711Z","phase":"Phase 1","brief_title":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","source_id_and_acronym":"NCT02390843 - AflacST1402","lead_sponsor":"Emory University","biomarkers":" STAT3 • IL6R","pipe":"","alterations":" ","tags":["STAT3 • IL6R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • simvastatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/22/2019","primary_completion_date":" 09/22/2019","study_txt":" Completion: 09/22/2019","study_completion_date":" 09/22/2019","last_update_posted":"2020-04-03"},{"id":"e3d70ec4-f879-4157-9ebe-eaa36fa0b809","acronym":"","url":"https://clinicaltrials.gov/study/NCT00690469","created_at":"2021-01-18T02:34:51.214Z","updated_at":"2024-07-02T16:36:54.774Z","phase":"","brief_title":"Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers","source_id_and_acronym":"NCT00690469","lead_sponsor":"Children's Oncology Group","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 234","initiation":"Initiation: 06/02/2008","start_date":" 06/02/2008","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2019-10-08"},{"id":"3a83fbdf-2a31-4464-a211-6d706585be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT02933333","created_at":"2021-01-18T14:24:30.992Z","updated_at":"2024-07-02T16:37:05.993Z","phase":"Phase 4","brief_title":"G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor","source_id_and_acronym":"NCT02933333","lead_sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Unknown status","enrollment":" Enrollment 405","initiation":"Initiation: 09/27/2016","start_date":" 09/27/2016","primary_txt":" Primary completion: 08/30/2020","primary_completion_date":" 08/30/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2018-10-17"}]